Katherine Fuh, MD, PhD
Associate Professor
Ob/Gyn, Reproductive Sciences
School of Medicine

Publications (75)

Top publication keywords:
Proto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesRecombinational DNA RepairDiscoidin Domain Receptor 2Endometrial NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsCancer-Associated FibroblastsBenzocycloheptenesIntercellular Signaling Peptides and ProteinsOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsNeoplasms, Glandular and EpithelialUterine NeoplasmsTriazolesPaclitaxel

• ROR2/Wnt5a signaling regulates directional cell migration and early tumor cell invasion in ovarian cancer.
  Molecular cancer research : MCR 2024 Grither WR, Baker B, Morikis VA, Ilagan MXG, Fuh KC, Longmore GD
• DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression.
  Oncogene 2023 Akinjiyan FA, Ibitoye Z, Zhao P, Shriver LP, Patti GJ, Longmore GD, Fuh KC
• Epigenetic regulation during cancer transitions across 11 tumour types.
  Nature 2023 Terekhanova NV, Karpova A, Liang WW, Strzalkowski A, Chen S, Li Y, Southard-Smith AN, Iglesia MD, Wendl MC, Jayasinghe RG, Liu J, Song Y, Cao S, Houston A, Liu X, Wyczalkowski MA, Lu RJ, Caravan W, …
• Stromal DDR2 Promotes Ovarian Cancer Metastasis through Regulation of Metabolism and Secretion of Extracellular Matrix Proteins.
  Molecular cancer research : MCR 2023 Schab AM, Greenwade MM, Stock E, Lomonosova E, Cho K, Grither WR, Noia H, Wilke D, Mullen MM, Hagemann AR, Hagemann IS, Thaker PH, Kuroki LM, McCourt CK, Khabele D, Powell MA, Mutch DG, Zhao P, …
• Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival.
  Communications biology 2023 Kotnik EN, Mullen MM, Spies NC, Li T, Inkman M, Zhang J, Martins-Rodrigues F, Hagemann IS, McCourt CK, Thaker PH, Hagemann AR, Powell MA, Mutch DG, Khabele D, Longmore GD, Mardis ER, Maher CA, Miller …

Show all (70 more) Hide

• Reproductive Scientist Development Program: Bridging the Gap to the Physician Scientist Career.
  Reproductive sciences (Thousand Oaks, Calif.) 2023 Lo JO, Boniface ER, Heflin A, Stanic-Kostic AK, Fuh KC, Schust DJ
• Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays.
  Journal of visualized experiments : JoVE 2023 van Biljon L, Fashemi B, Rodriguez J, Graham O, Compadre A, Fuh K, Khabele D, Mullen M
• Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
  Journal of visualized experiments : JoVE 2023 Graham O, Rodriguez J, van Biljon L, Fashemi B, Graham E, Fuh K, Khabele D, Mullen M
• Identity-related experiences of Asian American trainees in gynecologic oncology.
  Gynecologic oncology reports 2022 Dholakia J, Lee YW, Lu KH, Huh WK, Yamada SD, Fuh KC, Kumar AS, Liang MI, Nair N, Kim KH
• Community access to primary care is an important geographic disparity among ovarian cancer patients undergoing cytoreductive surgery.
  Gynecologic oncology reports 2022 Zamorano AS, Mazul AL, Marx C, Mullen MM, Greenwade M, Stewart Massad L, McCourt CK, Hagemann AR, Thaker PH, Fuh KC, Powell MA, Mutch DG, Khabele D, Kuroki LM
• State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report.
  JCO precision oncology 2022 Ethier JL, Fuh KC, Arend R, Konecny GE, Konstantinopoulos PA, Odunsi K, Swisher EM, Kohn EC, Zamarin D
• High visceral fat to subcutaneous fat ratios portend a poor prognosis in patients with advanced endometrial cancer.
  Gynecologic oncology 2022 Buckley E, Mullen MM, Nizamuddin RA, Stein JH, Kuroki LM, Fuh KC, Hagemann AR, McCourt CK, Mutch D, Khabele D, Powell MA, Ippolito JE, Thaker PH
• Gynecologic oncology patient perspectives and knowledge on advance care planning: A quality improvement intervention.
  Gynecologic oncology reports 2022 Huepenbecker SP, Lewis S, Valentine MC, Palisoul ML, Thaker PH, Hagemann AR, McCourt CK, Fuh KC, Powell MA, Mutch DG, Kuroki LM
• GAS6-AXL Inhibition by AVB-500 Overcomes Resistance to Paclitaxel in Endometrial Cancer by Decreasing Tumor Cell Glycolysis.
  Molecular cancer therapeutics 2022 Bruce SF, Cho K, Noia H, Lomonosova E, Stock EC, Oplt A, Blachut B, Mullen MM, Kuroki LM, Hagemann AR, McCourt CK, Thaker PH, Khabele D, Powell MA, Mutch DG, Shriver LP, Patti GJ, Fuh KC
• DDR2 Expression in Cancer-Associated Fibroblasts Promotes Ovarian Cancer Tumor Invasion and Metastasis through Periostin-ITGB1.
  Cancers 2022 Akinjiyan FA, Dave RM, Alpert E, Longmore GD, Fuh KC
• Ridiculously good writing: How to write like a pro and publish like a boss.
  Gynecologic oncology reports 2022 Modesitt SC, Havrilesky LJ, Previs RA, Alejandro Rauh-Hain J, Michael Straughn J, Bakkum-Gamez JN, Fuh KC, Cohn DE
• Mismatch repair deficiency in ovarian cancer.
  Gynecologic oncology reports 2022 Fuh K
• Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment.
  Nature communications 2022 Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, …
• Impact of the COVID-19 pandemic on referral to and delivery of gynecologic oncology care.
  Gynecologic oncology reports 2022 Bruce SF, Huysman B, Bharucha J, Massad LS, Mullen MM, Hagemann AR, Fuh KC, McCourt CK, Thaker PH, Khabele D, Powell MA, Mutch DG, Kuroki LM
• Culturing Primary Human Mesothelial Cells.
  Methods in molecular biology (Clifton, N.J.) 2022 Mullen M, Noia H, Fuh K
• Inhibition of AXL and VEGF-A Has Improved Therapeutic Efficacy in Uterine Serous Cancer.
  Cancers 2021 Toboni MD, Lomonosova E, Bruce SF, Tankou JI, Mullen MM, Schab A, Oplt A, Noia H, Wilke D, Kuroki LM, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Khabele D, Mutch DG, Fuh KC
• GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.
  Molecular cancer research : MCR 2021 Mullen MM, Lomonosova E, Toboni MD, Oplt A, Cybulla E, Blachut B, Zhao P, Noia H, Wilke D, Rankin EB, Kuroki LM, Hagemann AR, Hagemann IS, McCourt CK, Thaker PH, Mutch DG, Powell MA, Mosammaparast N, …
• Phase 1b study of AVB-500 in combination with paclitaxel or pegylated liposomal doxorubicin platinum-resistant recurrent ovarian cancer.
  Gynecologic oncology 2021 Fuh KC, Bookman MA, Liu JF, Coleman RL, Herzog TJ, Thaker PH, Monk BJ, Anderson R, McIntyre G, Rangwala R, Moore KN
• Phase I Trial of Stereotactic MRI-Guided Online Adaptive Radiation Therapy (SMART) for the Treatment of Oligometastatic Ovarian Cancer.
  International journal of radiation oncology, biology, physics 2021 Henke LE, Stanley JA, Robinson C, Srivastava A, Contreras JA, Curcuru A, Green OL, Massad LS, Kuroki L, Fuh K, Hagemann A, Mutch D, McCourt C, Thaker P, Powell M, Markovina S, Grigsby PW, Schwarz JK, …
• Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment.
  Nature communications 2021 Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, …
• Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.
  The Journal of clinical investigation 2021 Qian J, LeSavage BL, Hubka KM, Ma C, Natarajan S, Eggold JT, Xiao Y, Fuh KC, Krishnan V, Enejder A, Heilshorn SC, Dorigo O, Rankin EB
• Text-message-based behavioral weight loss for endometrial cancer survivors with obesity: A randomized controlled trial.
  Gynecologic oncology 2021 Zamorano AS, Wilson EM, Liu J, Leon A, Kuroki LM, Thaker PH, McCourt CK, Fuh KC, Powell MA, Mutch DG, Evanoff BA, Colditz GA, Hagemann AR
• Radiation therapy for vaginal and perirectal lesions in recurrent ovarian cancer.
  Gynecologic oncology reports 2021 Johns EA, Stanley JA, Toboni MD, Schwarz JK, Zhang F, Hagemann AR, Fuh KC, Thaker PH, McCourt CK, Mutch DG, Powell MA, Khabele D, Kuroki LM
• Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
  Gynecologic oncology 2021 Gupta VG, Hirst J, Petersen S, Roby KF, Kusch M, Zhou H, Clive ML, Jewell A, Pathak HB, Godwin AK, Wilson AJ, Crispens MA, Cybulla E, Vindigni A, Fuh KC, Khabele D
• A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy.
  Gynecologic oncology 2021 Mullen MM, McKinnish TR, Fiala MA, Zamorano AS, Kuroki LM, Fuh KC, Hagemann AR, McCourt CK, Mutch DG, Powell MA, Wildes TM, Thaker PH
• Obese endometrial cancer survivors' perceptions of weight loss strategies and characteristics that may influence participation in behavioral interventions.
  Gynecologic oncology reports 2021 Wilson EM, Zamorano AS, Liu J, Morris D, Leon A, Kuroki LM, Thaker PH, McCourt CK, Fuh KC, Powell MA, Mutch DG, Colditz GA, Hagemann AR
• Impact of employment and insurance status on distress in gynecologic oncology patients.
  Gynecologic oncology 2021 Kuroki LM, Morris DH, Greenwade M, Landon M, Hagemann AR, Thaker PH, Massad LS, McCourt CK, Fuh KC, Powell MA, Mutch DG, Khabele D, Vanderlan JR
• The role of endometrial sampling for surveillance of recurrence in postmenopausal patients with medically inoperable stage I endometrial cancer.
  Gynecologic oncology reports 2020 Carey-Love A, Mullen MM, Zamorano A, Markovina S, Hagemann AR, Fuh KC, Thaker PH, Mutch DG, Powell MA, Kuroki LM
• Clinical assays for assessment of homologous recombination DNA repair deficiency.
  Gynecologic oncology 2020 Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF
• Homologous recombination deficiency real-time clinical assays, ready or not?
  Gynecologic oncology 2020 Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A
• Detection of a somatic GREB1-NCOA1 gene fusion in a uterine tumor resembling ovarian sex cord tumor (UTROSCT).
  Gynecologic oncology reports 2020 Grither WR, Dickson BC, Fuh KC, Hagemann IS
• A fellow-run clinic achieves similar patient outcomes as faculty clinics: A safe and feasible model for gynecologic oncology fellow education.
  Gynecologic oncology 2020 Buchanan TR, Johns EA, Massad LS, Dick R, Thaker PH, Hagemann AR, Fuh KC, McCourt CK, Powell MA, Mutch DG, Kuroki LM
• FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival.
  Gynecologic oncology 2020 Grigsby PW, Massad LS, Mutch DG, Powell MA, Thaker PH, McCourt C, Hagemann A, Fuh K, Kuroki L, Schwarz JK, Markovina S, Lin AJ, Dehdashti F, Siegel BA
• Proteogenomic Characterization of Endometrial Carcinoma.
  Cell 2020 Dou Y, Kawaler EA, Cui Zhou D, Gritsenko MA, Huang C, Blumenberg L, Karpova A, Petyuk VA, Savage SR, Satpathy S, Liu W, Wu Y, Tsai CF, Wen B, Li Z, Cao S, Moon J, Shi Z, Cornwell M, Wyczalkowski MA, …
• Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
  Gynecologic oncology 2019 Griffin NE, Buchanan TR, Smith SH, Leon AA, Meyer MF, Liu J, Tabak RG, Fuh KC, Thaker PH, Powell MA, Mutch DG, Massad LS, Colditz GA, Hagemann AR
• S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.
  Cancer research 2019 Xiao Y, Zhao H, Tian L, Nolley R, Diep AN, Ernst A, Fuh KC, Miao YR, von Eyben R, Leppert JT, Brooks JD, Peehl DM, Giaccia AJ, Rankin EB
• Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
  Gynecologic oncology 2019 Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS
• Type II endometrial cancers with minimal, non-invasive residual disease on final pathology: What should we do next?
  Gynecologic oncology reports 2019 Mills KA, Lopez H, Sun L, Cripe JC, Litz T, Thaker PH, Powell MA, Mutch DG, Fuh KC
• Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy?
  Gynecologic oncology reports 2019 Liang B, Lange SS, Massad LS, Dick R, Mills KA, Hagemann AR, McCourt CK, Thaker PH, Fuh KC, Mutch DG, Powell MA, Kuroki LM
• p5RHH nanoparticle-mediated delivery of AXL siRNA inhibits metastasis of ovarian and uterine cancer cells in mouse xenografts.
  Scientific reports 2019 Mills KA, Quinn JM, Roach ST, Palisoul M, Nguyen M, Noia H, Guo L, Fazal J, Mutch DG, Wickline SA, Pan H, Fuh KC
• Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis.
  Cancer research 2019 Natarajan S, Foreman KM, Soriano MI, Rossen NS, Shehade H, Fregoso DR, Eggold JT, Krishnan V, Dorigo O, Krieg AJ, Heilshorn SC, Sinha S, Fuh KC, Rankin EB
• Inpatient management of hypercalcemia portends a poor prognosis among gynecologic oncology patients: A trigger to initiate hospice care?
  Gynecologic oncology reports 2019 Cripe JC, Buchanan TR, Wan L, Hagemann AR, McCourt CK, Massad LS, Fuh KC, Mutch DG, Powell MA, Thaker PH, Kuroki LM
• Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer.
  Gynecologic oncology 2019 Cripe JC, Buchanan TR, Kuroki LM, Wan L, Mills KA, Massad L, Hagemann AR, Fuh KC, Mutch DG, Powell MA, Matsuo K, Thaker PH
• Untitled Publication
  Gynecologic oncology reports 2018 Huepenbecker SP, Wan L, Leon A, Rosen D, Hoff J, Kuroki LM, Fuh KC, Powell MA, Mutch DG, Colditz GA, Hagemann AR
• Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
  Molecular cancer therapeutics 2018 Quinn JM, Greenwade MM, Palisoul ML, Opara G, Massad K, Guo L, Zhao P, Beck-Noia H, Hagemann IS, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC
• SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
  Gynecologic oncology 2018 Mills KA, Roach ST, Quinn JM, Guo L, Beck HM, Lomonosova E, Ilivicky AR, Starks CM, Lawrence JA, Hagemann AR, McCourt C, Thaker PH, Powell MA, Mutch DG, Fuh KC
• Gynecologic Oncologists' Perceptions of Palliative Care and Associated Barriers: A Survey of the Society of Gynecologic Oncology.
  Gynecologic and obstetric investigation 2018 Cripe JC, Mills KA, Kuroki LK, Wan L, Hagemann AR, Fuh KC, Mutch DG, Powell MA, Thaker PH
• TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.
  Oncogene 2018 Grither WR, Divine LM, Meller EH, Wilke DJ, Desai RA, Loza AJ, Zhao P, Lohrey A, Longmore GD, Fuh KC
• Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.
  Molecular cancer therapeutics 2017 Palisoul ML, Quinn JM, Schepers E, Hagemann IS, Guo L, Reger K, Hagemann AR, McCourt CK, Thaker PH, Powell MA, Mutch DG, Fuh KC
• Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.
  F1000Research 2017 Mills K, Fuh K
• AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer.
  Oncotarget 2016 Divine LM, Nguyen MR, Meller E, Desai RA, Arif B, Rankin EB, Bligard KH, Meyerson C, Hagemann IS, Massad M, Thaker PH, Hagemann AR, McCourt CK, Powell MA, Mutch DG, Fuh KC
• Radiation Therapy for Recurrent Clear-Cell Cancer of the Ovary.
  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2016 Westhoff GL, Fuh KC, Longacre TA, McNally JL, Hsu IC, Kapp DS, Teng N, Chen LM
• The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
  Gynecologic oncology 2016 Chan JK, Java JJ, Fuh K, Monk BJ, Kapp DS, Herzog T, Bell J, Young R
• Summary of the 2016 American Association for Cancer Research (AACR) Annual Meeting.
  Gynecologic oncology 2016 Fuh K, Vlad AM, Landen CN
• Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
  Gynecologic oncology 2015 Fuh KC, Secord AA, Bevis KS, Huh W, ElNaggar A, Blansit K, Previs R, Tillmanns T, Kapp DS, Chan JK
• Survival differences of Asian and Caucasian epithelial ovarian cancer patients in the United States.
  Gynecologic oncology 2014 Fuh KC, Shin JY, Kapp DS, Brooks RA, Ueda S, Urban RR, Chen LM, Chan JK
• Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
  Proceedings of the National Academy of Sciences of the United States of America 2014 Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A, Lindgren D, Axelson H, Miao YR, Krieg AJ, Giaccia AJ
• Concomitant chemotherapy and radiation for the treatment of advanced-stage endometrial cancer.
  Gynecologic oncology 2014 Wilkinson-Ryan I, Binder PS, Pourabolghasem S, Al-Hammadi N, Fuh K, Hagemann A, Thaker P, Schwarz J, Grigsby P, Mutch D, Powell M
• Utilization of and charges for robotic versus laparoscopic versus open surgery for endometrial cancer.
  Journal of surgical oncology 2012 Yu X, Lum D, Kiet TK, Fuh KC, Orr J, Brooks RA, Ueda SM, Chen LM, Kapp DS, Chan JK
• Current management of vulvar cancer.
  Hematology/oncology clinics of North America 2012 Fuh KC, Berek JS
• AXL is an essential factor and therapeutic target for metastatic ovarian cancer.
  Cancer research 2010 Rankin EB, Fuh KC, Taylor TE, Krieg AJ, Musser M, Yuan J, Wei K, Kuo CJ, Longacre TA, Giaccia AJ
• Oral misoprostol and vaginal isosorbide mononitrate for labor induction: a randomized controlled trial.
  Obstetrics and gynecology 2010 Collingham JP, Fuh KC, Caughey AB, Pullen KM, Lyell DJ, El-Sayed YY
• Daily compared with 8-hour gentamicin for the treatment of intrapartum chorioamnionitis: a randomized controlled trial.
  Obstetrics and gynecology 2010 Lyell DJ, Pullen K, Fuh K, Zamah AM, Caughey AB, Benitz W, El-Sayed YY
• The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?
  British journal of cancer 2008 Chan J, Fuh K, Shin J, Cheung M, Powell C, Chen LM, Kapp D, Osann K
• Mesenteric hemodynamic response to circulatory shock.
  Current opinion in critical care 2003 Ceppa EP, Fuh KC, Bulkley GB
• Signal transduction by reactive oxygen species: alternative paradigms for signaling specificity.
  Surgery 2002 Fuh KC, Meneshian A, Patel CB, Takiar V, Bulkley GB
• The mesenteric hemodynamic response to circulatory shock: an overview.
  Shock (Augusta, Ga.) 2001 Reilly PM, Wilkins KB, Fuh KC, Haglund U, Bulkley GB
• Hemodynamic pathogenesis of ischemic hepatic injury following cardiogenic shock/resuscitation.
  Shock (Augusta, Ga.) 2000 Bailey RW, Brengman ML, Fuh KC, Hamilton SR, Herlong HF, Bulkley GB
• Endothelial cells potentiate phagocytic killing by macrophages via platelet-activating factor release.
  American journal of physiology. Heart and circulatory physiology 2000 Owaki T, Meneshian A, Maemura K, Takao S, Wang D, Fuh KC, Bulkley GB, Klein AS
• Mesenteric vasoconstriction in response to hemorrhagic shock.
  Shock (Augusta, Ga.) 2000 Toung T, Reilly PM, Fuh KC, Ferris R, Bulkley GB